FDA approves Lenz Therapeutics’ VIZZ for the treatment of presbyopia
Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.
ASRS 2025: ASRS 2025: Suprachoroidal avoralstat stops vascular leakage in a well-established rabbit model
Q&A: Updates on faricimab for DME from ASRS 2025
Q&A: A VERONA trial update with Yasha S. Modi, MD
Yasha S. Modi, MD, discusses promising results from the VERONA study on EYP-1901, a potential treatment for diabetic macular edema.
EyePoint completes enrollment of LUGANO and LUCIA trials
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.
Opus Genetics partners with Global RDH12 Alliance
Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.
Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer
Haller expands her leadership role of ophthalmologist-in-chief following the retirement of longtime executive Joseph P. Bilson.
Topcon acquires Intelligent Retinal Imaging Systems, bolstering AI-powered screenings
Integrating IRIS technologies will allow Topcon to improve retinal disease diagnostics and referrals from primary care providers.
S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
The DRD Cure Accelerator, highlighted at the CCOI-Stanford Summit, is a global initiative advancing clinical research and collaborations to eliminate vision loss from diabetic retinal disease.
Retinal microvasculature on OCTA may predict coronary artery disease risk
Japanese researchers link outdoor time to rapid increase in choroidal thickness
Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point
What to expect from ASRS 2025
In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Ophthalmology spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event.
Alcon to showcase next-gen retina tools and clinical data at ASRS annual meeting
Notably, Alcon will be providing a demo of the UNIPEXY Gas Delivery System
Bascom Palmer Eye Institute ranked as top ophthalmology hospital in US for 22nd year in a row
The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 15 specialties and 22 procedures and conditions.
Alteogen receives positive CHMP opinion for aflibercept biosimilar, EYLUXVI
Re-Vana and Boehringer Ingelheim launch $1B collaboration to develop extended-release eye therapies
CORXEL submits NDA for LNZ100 in China for presbyopia treatment
LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022.
Alkeus Pharmaceuticals to present TEASE and SAGA study data at ASRS 2025
Discover groundbreaking findings on oral gildeuretinol's impact on Stargardt disease at the ASRS 43rd Annual Meeting in Long Beach, California.
Part 7: Looking back at 50 years of innovation in ophthalmology
To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
Most Americans avoid eye exams due to perceived non-urgency, confusion about benefits
A recent study reveals that many Americans neglect eye care due to cost and urgency misconceptions, despite the significant impact on daily life.
Part 6: Looking back at 50 years of innovation in ophthalmology
NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
Q&A: Natalie Afshari, MD, FACS, championing on-label pediatric IOLs: turning advocacy into access
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy
Vonaprument has received fast track designation from the US Food and Drug Administration.
Kiora Pharmaceuticals Secures US Patent for KIO-104
KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and complications as a result of refractive surgery.
Scuba divers and surfers face dual light exposure that may accelerate AMD
Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.
Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence
At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.
Part 5: Looking back at 50 years of innovation in ophthalmology
